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Objective: To determine the stability and the degree of variation of antiphospholipid antibody (aPL) results
over time in a large cohort of well evaluated aPL positive patients; and to analyse factors contributing to
aPL variation and the validity of aPL in a real world setting in which aPL tests are done in multiple
laboratories.
Methods: The clinical characteristics, drug treatment, and 1652 data points for lupus anticoagulant (LA),
anticardiolipin antibodies (aCL), and anti-b2 glycoprotein I antibodies (anti-b2GPI) were examined in 204
aPL positive patients; 81 of these met the Sapporo criteria for antiphospholipid syndrome (APS) and 123
were asymptomatic bearers of aPL.
Results: 87% of initially positive LA results, 88% of initially negative to low positive aCL results, 75% of
initially moderate to high positive aCL results, 96% of initially negative to low positive anti-b2GPI results,
and 76% of initially moderate to high positive anti-b2GPI results subsequently remained in the same range
regardless of the laboratory performing the test. Aspirin, warfarin, and hydroxychloroquine use did not
differ among patients whose aCL titres significantly decreased or increased or remained stable. On same
day specimens, the consistency of aCL results among suppliers ranged from 64% to 88% and the
correlation ranged from 0.5 to 0.8. Agreement was moderate for aCL IgG and aCL IgM; however, for aCL
IgA agreement was marginal.
Conclusions: aPL results remained stable for at least three quarters of subsequent tests, regardless of the
laboratory performing the test; the small amount of variation that occurred did not appear to be caused by
aspirin, warfarin, or hydroxychloroquine use.
I
n patients with thrombosis or pregnancy complications, a
persistently positive antiphospholipid antibody (aPL)
(lupus anticoagulant test (LA), anticardiolipin antibodies
(aCL), and anti-b2 glycoprotein I antibodies (anti-b2GPI))
establishes a classification of definite antiphospholipid
syndrome (APS).1 In a clinical setting, physicians judging
aPL tests face several challenges. First, aPL in individual
patients may vary over time, though how much spontaneous
variation occurs is unknown. Second, it is also unknown
whether any variation that does occur reflects autoimmune
disease activity, drug treatment, or interlaboratory differ-
ences. Third, interlaboratory correlation among aCL results is
not well established—a point particularly important in the
USA where, because of rapidly changing insurance coverage
systems, physicians can no longer specify the laboratories in
which their patients’ specimens are tested.
The primary objective of this study was to determine the
stability and the degree of variation of aPL results over time
in a large cohort of well evaluated aPL positive patients.
Second, we analysed factors we considered likely to con-
tribute to aPL variation, and the validity of aPL in a real world
setting in which aPL tests are done in multiple laboratories.
The results should offer guidance to practising physicians and
researchers in the management of aPL positive patients.
METHODS
We identified aPL positive patients from those entered into
two databases: a national antiphospholipid syndrome colla-
borative registry (APSCORE)2; and an asymptomatic (no
history of vascular or pregnancy events) aPL positive registry
(APLASA).3 Inclusion criteria were: positive aPL (aCL or LA
test or both, on two occasions six weeks apart), with or
without APS classification (based on the Sapporo criteria) for
APSCORE; and positive aPL without APS classification for
APLASA. We reviewed medical and registry records for all
available aPL tests (LA test, aCL, and anti-b2GPI) including
testing dates and laboratories. In addition, we also reviewed
demographic variables, definite and possible aPL related
clinical manifestations (venous and arterial thrombosis,
pregnancy morbidity, livedo reticularis, thrombocytopenia,
and migraine), coexisting autoimmune diseases, comorbid-
ities (hypertension requiring antihypertensive agents, dia-
betes mellitus requiring antidiabetic agents,
hypercholesterolaemia requiring cholesterol lowering agents,
and current smoking), and drug treatments.
Lupus anticoagulant tests were grouped as positive and
negative, based on the guidelines of the International Society
on Thrombosis and Hemostasis.4 The aCL and anti-b2GPI
results were expressed as their immunoglobulin subclasses
(aCL: IgG, IU or GPL U/ml; IgM, IU or MPL U/ml; and IgA, IU
or APL U/ml; anti-b2GPI: IgG, U/ml; IgM, U/ml; and IgA, U/
ml). They were divided into four groups: 0–19 U (negative);
20–39 U (low positive); 40–80 U (moderate positive); and
.80 U (high positive). We classified aPL positive patients
into three groups: vascular events with or without pregnancy
events (Sapporo APS classification criteria were met);
pregnancy events only (Sapporo APS classification criteria
were met); and asymptomatic (Sapporo APS classification
criteria were not met; patients with solely non-Sapporo aPL
Abbreviations: aCL, anticardiolipin antibody; aPL, antiphospholipid
antibody; APLASA, asymptomatic aPL positive registry; APS,
antiphospholipid syndrome; APSCORE, antiphospholipid syndrome
collaborative registry; GPI, glycoprotein I; LA, lupus anticoagulant
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manifestations such as livedo reticularis or cardiac valve
disease were also included in this group).
We arbitrarily selected the initial aPL result as the anchor.
Stability of aPL was defined as the percentage of subsequent
results in the same group; variation of aPL was defined as the
percentage of subsequent results in different groups. The
relations between clinically relevant variation (positive v
negative for LA test, negative to low v moderate to high titre
for aCL and anti-b2GPI tests) and aPL related clinical
manifestations or drug treatment (aspirin, warfarin, hydro-
xychloroquine) were analysed (x2 test) independently of
other manifestations of autoimmune disease activity.
To examine interlaboratory variation, we identified aPL
positive patients who had same specimen aCL testing from
different commercial suppliers and from our immunology
laboratory. Same specimen aCL results from different sources
were analysed for: consistency (percentage of results within the
same group); agreement between aCL groups (Cohen’s k test);
and correlation between aCL results (Spearman rank correla-
tion test to test the direction and strength of the relation).
RESULTS
Two hundred and four patients had positive low-medium-
high titre aCL or LA test or both; table 1 gives their
demographic and clinical characteristics. Fifty seven had
had vascular events (21 venous only, 30 arterial only, and six
venous and arterial). Table 2 gives the clinical characteristics
and drug treatment of aPL positive patients who had vascular
or only pregnancy event, or were asymptomatic at the time of
the study entry. Patients with vascular events more often had
livedo reticularis, migraine, hypertension, hypercholestero-
laemia, and concomitant LA and aCL positivity (p,0.05).
We identified 1652 aPL tests between 1984 and 2004: 387
LA tests (61% done at our institution and 39% at other
laboratories); 1097 aCL IgG/M/A tests (58% done using our in
house assay, 24% at Quest Diagnostics, 12% at other
Table 1 Demographic and clinical characteristic of 204
antiphospholipid antibody positive patients
Characteristic
Female 190 (93%)




African American 21 (10%)
Other 14 (7%)
APS as per Sapporo criteria 81
Vascular with/without pregnancy event 57
Pregnancy event only 24
Asymptomatic aPL positive patients 123
Values are n (%) or *mean (SD).
aPL, antiphospholipid antibody; APS, antiphospholipid syndrome.
Table 2 Clinical characteristic of 204 antiphospholipid antibody positive patients based
on the three patient groups
Characteristic V ¡ P event P event only Asymptomatic
Number of patients 57 24 123
Age (years) (mean (SD)) 43.5 (11.7) 43.0 (10.0) 47.6 (14.2)
No other CTD 27 (47%)a 8 (33%)b 16 (13%)ab
Undifferentiated CTD 7 (12%) 1 (4%) 30 (24%)
SLE* 21 (37%) 14 (58%) 56 (46%)
Livedo reticularis 11 (19%)a 4 (16%) 10 (8%)a
History of thrombocytopenia 11 (19%) 1 (4%) 11 (14%)
Migraine 23 (40%)a 5 (20%) 24 (20%)a
Hypertension 22 (39%)a 4 (16%) 22 (18%)a
Diabetes mellitus 2 (4%) 0 (0%) 4 (3%)
Hypercholesterolaemia 10 (18%)ab 0 (0%)b 6 (5%)a
Current smoking 3 (5%) 3 (12%) 15 (12%)
aPL tests
LA (+) and aCL (2) 2 (4%) 3 (13%) 13 (11%)
LA (+) and aCL (+) 28 (49%)a 11 (46%)b 22 (18%)ab
LA (2) and aCL (+) 17 (30%) 8 (23%) 55 (45%)
LA unknown and aCL (+) 10 (18%) 2 (8%) 33 (27%)
Drug treatment
Warfarin 37 (65%) 0 0
Clopidogrel 4 (7%) 0 0
Aspirin/dipyridamole 1 (2%) 0 0
LMWH 5 (9%) 0 0
Aspirin 9 (16%) 24 (100%) 55 (45%)
No treatment` 1 (2%) 0 17 (14%)
aa, bb Statistical significance (p,0.05) between groups (no statistical test was applied to the drug treatment section).
*Based on the American College of Rheumatology criteria.
Excluding patients who were randomised to receive daily aspirin 81 mg or placebo.
`No anticoagulant or antiplatelet agents.
aCL, anticardiolipin antibody; aPL, antiphospholipid antibody; CTD, connective tissue disorder; LA, lupus
anticoagulant; LMWH, low molecular weight heparin; P, pregnancy; SLE, systemic lupus erythematosus; V,
vascular.
Table 3 Testing laboratories and assays of
antiphospholipid antibodies
aPL test Testing laboratory and assay
LA test In house (DVV testH and DVV confirmH by American
Diagnostic Inc)
aCL test In house (based on Harris Standards*)
Quest Diagnostics (Pharmacia Diagnostics aCL kit)
APSCORE (based on Harris standards*)
Anti-b2GPI Quest Diagnostics (The Binding Site anti-b2GPI kit)
APSCORE (Inova Diagnostics anti-b2GPI kit)
*Harris EN, Pierangeli SS. Revisiting the anticardiolipin test and its
standardization. Lupus 2002;11:269–75.
aPL, antiphospholipid antibody; APSCORE, antiphospholipid syndrome
collaborative registry.
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laboratories, and 6% by the APSCORE assay); and 168 anti-
b2GPI IgG/M/A tests (54% done at Quest Diagnostics, 37% by
the APSCORE assay, and 9% at other laboratories) (table 3).
Of 159 patients tested for LA, 96 (60%) had more than one
LA test (total / mean (SD) / median number of LA tests in 96
patients: 324 / 3.5 (1.8) / 3; mean follow up time, 2.4 years).
Fifty one initial tests were positive, of which 37 (73%)
remained positive based on the final test (mean follow up, 2.1
years; mean number of repeat tests, 2.2); 39 of 51 patients
(77%) with an initial positive LA test had persistent LA
positivity and 82 of 94 subsequent tests (87%) from 51
patients were positive. Forty five tests were initially negative,
of which 37 (82%) remained negative based on the final test
(mean follow up, 2.7 years; mean number of repeat tests,
2.7); 40 of 45 patients (89%) with an initially negative LA test
had persistent LA negativity, and 121 of 134 subsequent tests
(90%) from 45 patients were negative.
One hundred and seventy nine of 204 patients (88%) had
more than one aCL test (total / mean (SD) / median number
of aCL tests in 179 patients: 1072 / 6.2 (4.7) / 4; mean follow
up time, 3.5 years). The highest isotype of the initial test was
IgG, IgM, and IgA for 106, 54, and 19 persons, respectively
(IgG and IgM for three (analysed as IgG), and IgM and IgA
for two (analysed as IgM)). Nine patients had isolated aCL
IgA positivity (LA status unknown in four). Table 4 shows the
distribution of patients based on the highest initial aCL test;
the change in the aCL groups based on the final aCL test; and
the stability of aCL tests over time. The combined stability of
aCL was 88% for negative to low positive and 75% for
moderate to high positive groups. Furthermore, 71% of
patients with an initial negative to low positive aCL result
and 62% of patients with an initial medium to high positive
aCL result had all of the subsequent aCL results in the same
range.
One hundred and nine persons had anti-b2GPI tests but
only 27 (13%) had more than one (total / mean (SD) /
median number of anti-b2GPI tests in 27 patients: 87 / 3.2
(1.5) / 2; mean follow up time, 1.0 years). The highest isotype
of the initial test was IgG, IgM, and IgA for 11, 9, and 1
persons, respectively (six were reported as negative for all the
isotypes). Table 5 shows the change in the anti-b2GPI for
patients with more than one test. Ninety six per cent of
subsequent tests in patients with an initial anti-b2GPI titre of
,40 U/ml and 76% of subsequent tests in patients with an
initial anti-b2GPI titre of >40 U/ml remained in the same
group. Furthermore, 83% of patients with an initial negative
to low positive anti-b2GPI result and 67% of patients with an
initial medium to high positive anti-b2GPI result had all of
the subsequent anti-b2GPI results in the same range.
Excluding asymptomatic patients participating in a trial
testing low dose aspirin v placebo, aspirin, warfarin, and
hydroxychloroquine use did not differ between persons
whose aCL titres decreased from medium to high to negative
Table 4 The number of patients based on the highest initial anticardiolipin antibody (aCL) isotype, the change in the groups
based on the final aCL tests, and the stability of aCL tests over time
0–19 U 20–39 U 40–80 U >80 U
Highest initial aCL result (No of patients) 42 51 39 47
Analysis based on the final aCL results
Final aCL in the same group* 29 (69%) 16 (31%) 9 (23%) 31 (66%)
Final aCL in a lower group* – 21 (41%) 21 (54%) 16 (34%)`
Final aCL in a higher group* 13 (31%) 14 (28%) 9 (23%) –
Analysis based on total aCL results
Total number of aCL tests 226 302 241 338
Mean number of aCL tests 5.4 5.9 6.2 7.2
Total subsequent aCL results remaining in same group (stability, based on four groups) 59% 53% 50% 74%
0–39 U >40 U
Analysis based on total aCL results
Total number of aCL tests 528 579
Mean number of aCL tests 5.7 6.7
Total number of subsequent aCL tests 435 493
Patients in whom all of the subsequent aCL results were in the same range 66 (71%) 53 (62%)
Total subsequent aCL results remaining in same group (stability, based on two groups)1 88% 75%
Values are n, n (%), or %.
*The number and percentage of patients in the same group, a lower group, and a higher group based on a comparison between the initial and final aCL test result.
The highest initial isotype was different than the highest last isotype but were in the same group (,40 v >40 U) in 13 patients.
8/21 final aCL tests were in the negative and 13/21 tests were in the 20–39 U range.
`2/16 final aCL tests were in the negative range, 6/16 tests were in the 20–39 U, and 8/16 test were in the 40–80 U range.
119/528 (3.6%) of the aCL test results that switched from ‘‘low to medium’’ to ‘‘medium to high’’ titres were in the range of 40–45 U; and 21/579 (3.6%) of the
aCL test results that switched from ‘‘medium to high’’ to ‘‘low to medium’’ titres were in the range of 34–39 U.
aCL, anticardiolipin antibody.
Table 5 The number of patients based on the initial anti-
b2GPI test, the change in the groups based on the final
anti-b2GPI tests, and the stability of anti-b2GPI tests over
time
0–39 U >40 U
The highest initial anti-b2GPI result (No of
patients) 12 15
Analysis based on the final anti-b2GPI results
Final anti-b2GPI in the same group* 11 (92%) 11 (73%)
Analysis based on total anti-b2GPI results
Total number of anti-b2GPI tests 30 57
Mean number of anti-b2GPI tests 2.5 3.8
Total number of subsequent anti-b2GPI tests 18 42
Patients in whom all subsequent anti-b2GPI results
were in the same range 10 (83%) 10 (67%)
Total subsequent anti-b22GPI results remaining in
same group (stability) 96% 76%
Values are n, n (%), or %.
*The number and percentage of patients in the same group based on a
comparison between the initial and final anti-b2GPI test results.
b2GPI, b2 glycoprotein I.
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to low (n=26), increased from negative to low to medium to
high (n=13), or remained stable (n=65) (p=0.93,
p=0.13, and p=0.83, respectively). Similarly, definite and
possible aPL related clinical manifestations were not statis-
tically different between the patients whose aCL titres
decreased, increased, or remained stable. The diagnosis of
SLE was present in 35%, 62%, and 41% of patients whose aCL
titres decreased, increased, or remained stable, respectively
(p=0.2). When 91 SLE patients were compared with 51
patients with no connective tissue disorders, there was no
statistical difference between the number of patients whose
aCL titres decreased (12% v 22%, p=0.25), increased (12% v
6%, p=0.34), or remained stable (76% v 72%, p=0.72).
Thirty one patients had same specimen aCL tests by our
institution’s in house assay and APSCORE; 75 by our in
house assay and Diamedix Diagnostics aCL kit; and 77 by our
in house assay and Inova Diagnostics aCL kit. Table 6 shows
the consistency, agreement, and correlation between our
institution’s in house assay and other aCL kits. The
consistency ranged from 64% to 88% and the correlation
ranged from 0.5 to 0.8. Agreement was moderate for aCL IgG
and aCL IgM; agreement for aCL IgA was marginal.
DISCUSSION
Our data show that aPL results remain stable for at least
three quarters of subsequent tests during a mean follow up of
2.4 years for the LA test, 3.5 years for the aCL test, and 1.0
year for the anti-b2GPI test. The small amount of variation
that occurs does not appear to result from aspirin, warfarin,
or hydroxychloroquine use.
The Sapporo criteria require, without definition, medium
to high titre aCL is to make the diagnosis of APS.1 Different
clinical laboratories define ‘‘medium to high titre aCL’’ as
more than 15–20 international units (IU), 2.0–2.5 times the
median, or the 99th centile of normal population titres. In the
absence of consensus among laboratories5 or APS experts6
about what constitutes medium to high titre aCL, several
studies concluded that more than 40 IU or GPL U/ml is more
predictive of thrombotic events7–11 than lower titres. We used
a cut off aCL limit of 40 U for ‘‘medium to high titre aCL’’
and found that, regardless of the laboratory carrying out the
test, if the initial aCL result was less than 40 U, the
probability of obtaining a repeat study within the same
range in the next 3.5 years was 88%. If the initial aCL result
was equal to or more than 40 U, the probability that a second
test will also be in the same range was 75%. Antiphospholipid
antibodies bind primarily to the negatively charged phos-
pholipids through the phospholipid binding plasma protein
b2GPI, and some APS patients may have only anti-b2GPI
antibodies.12–13 Despite the small number of patients, we also
found that anti-b2GPI results of less than or more than 40 U/
ml were stable in at least three quarters of subsequent tests.
Similarly, at least three quarters of LA tests stayed either
positive or negative. Although our study was not primarily
designed to test this question, we found that concurrent
positivity of LA and aCL tests, traditional thrombosis risk
factors, livedo reticularis, and migraine were more common
in APS patients with vascular events than in aPL positive
asymptomatic persons. These results are consistent with
other studies showing that a positive LA test is more
commonly associated with thrombosis than is aCL,14 and
that dual positivity of aCL and LA test is more commonly
associated with thrombosis than is single positivity of aCL or
LA test.15
Infection induced transient aPL positivity is common in the
general population and usually not pathogenic. Vila et al
analysed 552 healthy donors for the prevalence of aPL and
found that 86% of positive IgG aCL and 97% of positive IgM
aCL tests were negative in one year.16 As our study population
derives from registries that require two positive aPL results as
inclusion criteria, our results do not apply to patients with
single aPL positivity.
Although McCarty et al reported that aPL decreased in
patients treated with hydroxychloroquine 200 mg twice daily
and aspirin 81 mg once daily,17 we did not observe any
relation between aspirin, warfarin, or hydroxychloroquine
treatment and change in aCL titre. The retrospective nature of
the study did not allow us to analyse corticosteroid or
immunosuppressive drug use accurately.
In order to determine the possible contribution of inter-
laboratory differences to aPL variation, we analysed the
degree of variation between aCL kits. Based on same day
specimens, the consistency of aCL results among different
suppliers ranged from 64% to 88%, with moderate agreement
for IgG and IgM. The agreement for aCL IgA was marginal.
Although interlaboratory agreement is better when positive
aCL results are compared in semiquantitative measures
(ranges of positivity),18 others also found medium agreement
between kits especially for IgG aCL.19 We did not analyse
interlaboratory variations between anti-b2GPI antibody kits;
however, Reber et al showed that anti-b2GPI antibody kits are
also poorly standardised, especially at lower titres, and the
agreement is better with medium to high titre IgG anti-
b2GPI.
20 Thus physicians should be conservative in their
interpretation of aCL and anti-b2GPI levels in individual
patients when results from multiple laboratories are avail-
able, a common scenario in the USA. The standardisation of
aCL and anti-b2GPI assays can still be improved to provide
better agreement, a point also noted by others.21 Nonetheless,
although interlaboratory differences might have contributed
to the degree of aPL variation over time, we found that at
least three quarters of aPL results were stable in the range of
negative to low and moderate to high over time.
Table 6 The consistency, agreement, and correlation between our in house assay and
other aCL kits
aCL kits n Consistency Agreement Correlation
IHA v APSCORE IgG 31 81% 0.66 0.8
IHA v APSCORE IgM 31 81% 0.46 0.8
IHA v APSCORE IgA 31 68% 0.15 0.5
IHA v Diamedix IgG 75 81% 0.4 0.6
IHA v Diamedix IgM 75 88% 0.4 0.8
IHA v Diamedix IgA 75 88% 0.2 0.6
IHA v Inova IgG 77 78% 0.5 0.8
IHA v Inova IgM 77 64% 0.3 0.8
IHA v Inova IgA 77 71% 0.2 0.7
APSCORE, antiphospholipid syndrome collaborative registry; IHA, in house assay.
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Our study has several limitations. It could not evaluate the
effect of SLE activity on aPL variation, a point argued by some
investigators22 but contradicted by others.23 Second, our titre
groupings were arbitrary but consistent with clinical experi-
ence. Within these ranges, aPL variation was low. However,
the clinical significance of our cut off points requires further
verification. Third, aPL tests from multiple laboratories were
included in our analysis; however, this was intentional in
order to simulate a real world experience in which multiple
and visit to visit comparisons must rely on studies done in
different laboratories owing to rapidly changing insurance
coverage systems. Lastly, the study did not evaluate aPL
variation beyond three to four years, and it is possible that
more variation may be observed with longer follow up.
Conclusions
Repeat aPL results remain stable for at least three quarters of
subsequent tests regardless of the laboratory carrying out the
test. The variation that occurs does not appear to result from
aspirin, warfarin, or hydroxychloroquine use. Although it is
unknown if and what level of aPL variation has clinical
significance, our findings should offer guidance to practising
physicians and researchers in the management of aPL
positive patients.
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